Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen’s desire to land its next blockbuster drug — or two — has been put on hold. The Federal Trade Commission sued Amgen in an effort to block the company’s proposed acquisition of Horizon Therapeutics for nearly $28 billion, citing concerns that it would…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
